Keyhole-Limpet Haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma

W. G. Walsh, P. Tomashefsky, C. A. Olsson, Ralph W deVere White

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The antigenicity of transitional cell carcinoma of the bladder has stimulated the search for effective immunotherapeutic agents in the treatment of this disease. Non-specific immunotherapy with local (intravesical/intralesional) and systemic Keyhole Limpet Haemocyanin (KLH) in a FANFT induced murine bladder tumor model was studied. Results showed no difference between control or treated groups in either tumor growth or animal survival.

Original languageEnglish (US)
Pages (from-to)263-265
Number of pages3
JournalUrological Research
Issue number6
StatePublished - Nov 1983
Externally publishedYes


  • Bladder carcinoma
  • Immunotherapy
  • Keyhole limpet haemocyanin (KLH)

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Keyhole-Limpet Haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma'. Together they form a unique fingerprint.

Cite this